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Abstract
Background: Non-muscle invasive bladder neoplasms with invasion of the lamina propria (stage T1) or high grade
of dysplasia are at "high risk" of progression to life-threatening cancer. However, the individual course is difficult
to predict. Chromosomal instability (CI) is associated with high tumor stage and grade, and possibly with the risk
of progression.
Methods: To investigate the relationship between CI and subsequent disease progression, we performed a case-
control-study of 125 patients with "high-risk" non-muscle invasive bladder neoplasms, 67 with later disease
progression, and 58 with no progression. Selection criteria were conservative (non-radical) resections and full
prospective clinical follow-up (> 5 years). We investigated primary lesions in 59, and recurrent lesions in 66 cases.
We used Affymetrix GeneChip® Mapping 10 K and 50 K SNP microarrays to evaluate genome wide chromosomal
imbalance (loss-of-heterozygosity and DNA copy number changes) in 48 representative tumors. DNA copy
number changes of 15 key instability regions were further investigated using QPCR in 101 tumors (including 25
tumors also analysed on 50 K SNP microarrays).
Results: Chromosomal instability did not predict any higher risk of subsequent progression. Stage T1 and high-
grade tumors had generally more unstable genomes than tumors of lower stage and grade (mostly non-primary
tumors following a "high-risk" tumor). However, about 25% of the "high-risk" tumors had very few alterations.
This was independent of subsequent progression. Recurrent lesions represent underlying field disease. A separate
analysis of these lesions did neither reflect any difference in the risk of progression. Of specific chromosomal
alterations, a possible association between loss of chromosome 8p11 and the risk of progression was found.
However, the predictive value was limited by the heterogeneity of the changes.
Conclusion: Chromosomal instability (CI) was associated with "high risk" tumors (stage T1 or high-grade), but
did not predict subsequent progression. Recurrences after "high-risk" tumors had fewer chromosomal
alterations, but there was no association with the risk of progression in this group either. Thus, the prediction of
progression of "high risk" non-muscle invasive bladder tumors using chromosomal changes is difficult. Loss of
chromosome 8p11 may play a role in the progression process. About 25% of the "high risk" tumors were
chromosomal stable.
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Background
The individual course of non-muscle invasive bladder
neoplasm is difficult to predict. In particular, tumors with
invasion of the lamina propria (stage T1) or high grade of
dysplasia have a 30–60% risk of progression to muscle
invasive, life-threatening cancer [1,2]. A transurethral,
bladder-sparing approach is often chosen to cure non-
muscle invasive tumors. However, recurrence is common
[2,3]. Remnants of tumor tissue due to incomplete resec-
tion would be the source of true tumor recurrence at the
original site. New tumor occurrences at distant sites, how-
ever, are owed to cancer precursors in the mucosa – so-
called field disease – a very common condition in bladder
cancer. Multifocality or concomitant carcinoma in situ
(CIS), a highly dysplastic flat precursor lesion, may be
indicators of field disease. The evaluation of the malig-
nant potential of field disease is of particular clinical inter-
est.
The assessment of molecular changes may improve this
evaluation. The hitherto best known molecular event pre-
dictive of advanced malignant development is the loss of
p53 function, which is found in the majority of pro-
gressed bladder cancers and, notably, in CIS [4,5]. Several
mechanisms may lead to loss of p53 function, e.g. gene
mutation or loss, transcriptional downregulation and
enhanced degradation. P53 is part of the complex DNA
damage control system, which surveys the integrity of the
genome. Dysfunction of this system leads to chromo-
somal instability (CI), a key event of malignant tumor
development [6]. CI is easier to assess and to interpret
than loss of p53 function, and is currently employed for
the detection of tumor-cells in the urine using fluores-
cence in-situ hybridisation and microsatellite analysis [7].
Primary tumors and subsequent recurrences are usually of
clonal origin. Evaluation of the CI of recurrences may thus
gain insight into the malignant potential of field changes.
CI can possibly predict the risk of progression. Richter et
al [8] studied 54 stage T1 bladder cancers by conventional
comparative genomic hybridisation (CGH). This study
suggested that multiple chromosomal losses, as well as
copy number changes at certain genomic regions, herald a
shorter progression free survival and thus a worse progno-
sis [8]. Recent advances in microarray technology made it
possible to screen the genome for chromosomal imbal-
ances (= loss of heterozygosity (LOH) and/or DNA copy
number (CN) alterations) with high resolution [9-13].
Single nucleotide polymorphism (SNP) microarrays offer
the opportunity to study LOH and CN changes simultane-
ously [14]. We previously studied chromosomal instabil-
ity during the progression of bladder cancer using SNP
microarrays [10]. In this paper, we aimed at a genome-
wide investigation of inherent chromosomal alterations
related to the risk of progression in bladder cancer. We
present an extended material of 48 mostly high-risk non-
muscle invasive bladder cancers with special reference to
subsequent progression. Furthermore, we performed CN
analyses of 15 most frequently changed gene-loci using
quantitative polymerase chain reaction (QPCR) in 77
independent test tumors for validating the association of
the changes with the risk of progression of non-muscle
invasive bladder cancer.
Methods
Study design, patient selection and follow-up
This case-control study was based on a tissue bank with
samples from consecutive bladder cancer patients, treated
at our institution since 1994. Patients were followed pro-
spectively. The study was approved by the scientific ethical
committee of the county of Aarhus, and all patients gave
their informed written consent.
Bladder tumor specimens were cleaved immediately after
transurethral resection. One half was analysed by conven-
tional histopathology, the rest snap-frozen in liquid nitro-
gen and stored at -80°C. Tumors were staged according to
TNM and graded according to the Bergkvist-classification
[15] on a routine base.
We previously analysed tumors from 19 patients from this
cohort using Affymetrix® Early Access GeneChip® Mapping
10 K SNP microarrays (Affymetrix, Santa Clara, CA)
[10,16]. To study the impact of chromosomal alterations
on the risk of future disease progression, we extended this
dataset by retrospectively selecting further 106 patients
from the cohort to total 125 patients. Selection criteria,
besides the availability of material, were: non-muscle
invasive disease (no previous muscle invasion), a full clin-
ical follow-up without radical treatment (at least five
years), and a disease course with "high-risk" tumors (stage
T1 or grade 3) or progression (to muscle invasion or
metastasis). See Additional File 1 for clinical data of
patients and tumors.
Primary tumors from 59 patients were available. Most of
these tumors were "high-risk" (stage T1 or grade 3); how-
ever, we included 4 primary stage Ta grade 2 tumors with
later progression ("high-risk in retrospect") (Table 1). The
aim was to investigate inherent chromosomal alterations
related to the risk of progression in bladder cancer.
To investigate whether these changes also were present in
recurrences, i.e. in field disease, we examined non-pri-
mary tumors from 66 different patients. All but three were
followed for a previous "high-risk" tumor, but fifteen of
the non-primary tumors were "low-risk" themselves
(stage Ta grade 2) (Table 1). Non-primary and primary
tumors of this study were independent, i.e. from different
patients.BMC Cancer 2009, 9:149 http://www.biomedcentral.com/1471-2407/9/149
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Preselected site biopsies were taken to diagnose concomi-
tant CIS. No adjuvant intravesical chemotherapy was
given. Patients were followed prospectively in a routine
schedule. Disease recurrences were treated in a standard-
ized fashion. An induction course of intravesical Bacille
Calmette-Guerin instillations was applied in 30 cases (CIS,
multiple tumors, high recurrence rate), but was not stand-
ard treatment at that time. The progression-free survival
time was censored at the time of the last control cystos-
copy with no evidence of disease. Detailed clinical data
are available in Additional File 1.
DNA-purification and SNP microarray analysis
DNA from frozen tumor tissue and corresponding
genomic DNA from blood leucocytes was extracted and
purified using a standard DNA-extraction kit (Gentra,
Minneapolis, MN). Tumor tissue was trimmed in the
microscope to ensure at least 75% tumor cells. Previously
purified DNA (kept at -20 to -80°C) was used in some
cases, having been extracted using various methods,
including phenol and ethanol extraction. Concentration
and OD ratios were determined using a spectrophotome-
ter.
For high-resolution genome screening, we expanded the
previously analysed 10 K SNP microarray dataset of 19
tumors [16] with further 29 tumors to total 48 tumors. A
selection was made to achieve a homogeneous dataset
with respect to the distribution of primary/recurrent, stage
T1/stage Ta, and progression/no progression; otherwise it
was random. Due to technological progress, the Early
Access 10 K SNP microarray was no longer available;
instead we used contemporary Affymetrix Xba GeneChip®
Mapping 50 K SNP microarrays. Analyses of tumor and
corresponding blood-DNA were performed as prescribed
by the manufacturer. The method was similar for both
array types, however, the analyses were performed inde-
pendently of each other. In brief, 250 ng of DNA was
digested using Xba I restriction enzyme, ligated to an Xba
adaptor and amplified by PCR using adaptor-specific
primers. After purification, 40 μg of the PCR products
were fragmented using DNase I, labelled, and hybridised
to the microarrays at 48°C for 18 hours. After hybridisa-
tion, arrays were washed 2 times, stained with streptavi-
din-phycoerythin, washed, linked to biotinylated anti-
streptavidin antibodies, stained again, and finally washed,
followed by reading in a laser scanner. We used an auto-
mated Fluidics® station and the GCOS® software provided
by the manufacturer.
LOH-analysis
10 K and 50 K SNP array data were normalized and ana-
lysed independently, using empirical means and standard
deviations (sd) of 113 [10 K SNP arrays] and 67 [50 K SNP
arrays] normal DNA samples extracted from blood leuco-
cytes, respectively, as described [16]. To obtain allelic calls
for tumor DNA and the corresponding normal genomic
DNA, we used the GDAS® genotyping software supplied
by the array manufacturer. Subsequently, a Hidden
Markov Model was applied to infer the probability aij of
allelic imbalance/loss of heterozygosity (LOH) for each
SNP j on each tumor array i compared to the correspond-
ing array of normal DNA, using the DChip software. For
details, see http://biosun1.harvard.edu/complab/dchip/
Table 1: Stage and grade distribution of the study material of 125 non-muscle invasive bladder cancers.
Tumors with later progression Tumors with no progression Totals
Stage/Grade TaG2* TaG2 TaG3/CIS T1G2 T1G3 TaG2 TaG3/CIS T1G2 T1G3
Primary tumors SNP microarray 1 1 10 10 22
QPCR only 3 1 1 10 6 16 37
Total primary tumors 4 1 2 20 6 26 59
Secondary tumors SNP microarray 1 2 6 6 2 4 1 4 26
QPCR only 2 4 9 10 4 5 2 4 40
Total secondary tumors 3 6 15 0 16 6 9 3 8 66
Stage distribution (totals) 7 6 16 2 36 6 9 6 26 125
Mean age (range) 72.4 (54–85) 68.4 (46–83)
Gender Male 54 44 98
Female 13 14 27
Totals 67 58 125
Distribution into primary and secondary tumors, as well as the type of analysis performed, is indicated. Seven low-risk cases with later progression 
were included and marked with asterisk*. All other tumors were high-risk, or recurrence after high-risk tumors. Detailed clinical information about 
all individual cases including primary and current stage, grade, treatment, CIS-status, progression free survival, metastases, overall survival and 
causes of death are listed in Additional File 1.BMC Cancer 2009, 9:149 http://www.biomedcentral.com/1471-2407/9/149
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snp.htm, and [17]. For the calculation of the fraction of
the genome altered (FGA [LOH]), a probability a > 0.2
was considered as LOH for both array types.
Copy number analysis
10 K and 50 K SNP array data were normalized and ana-
lysed separately, as mentioned above. The arrays were
normalized and signal values for the individual SNPs were
extracted using the DChip software [14]. Briefly, an invar-
iant set normalization method was applied to normalize
all arrays of one type at the probe intensity level to a base-
line array. After normalization, the perfect match/mis-
match difference model was applied to extract a single
signal value for each SNP on each array.
Data was then normalized SNP-wise to have mean zero
and SD one, using the empirical mean and SD from the
respective normal arrays, zij = (yij - mj)/sdj, where yij is the
signal value for array i and SNP j, mj is the mean of SNP j
and sdj the SD of SNP j. Data zij was further smoothened
over k SNPs to obtain xij = Σ zik/k, where the sum is over k
= j - K,...,j+K. Here K = 5 for both 10 K and 50 K arrays. For
the calculation of the fraction of the genome altered (FGA
[CN]), signal values x  higher than 3 or lower than -3
(mean +/-3 sd, corresponding to probability p  of
1.degree's error < 0.01) were considered copy number
imbalanced.
Creation of common SNP dataset
A total of 6,400 common probesets were identified on
both microarrays, using the annotation-files provided by
the array-manufacturer. Data a (LOH probability) and x
(standardised signal value) for these SNPs were extracted
from both the 10 K and 50 K datasets and assigned to
unique reference-SNP-IDs http://www.ncbi.nlm.nih.gov/
SNP. The combined dataset included data from 48
patients, 19 analysed on 10 K arrays and 29 analysed on
50 K arrays. LOH data was missing for one 50 K array (#8-
3) because of unmatched blood-DNA, and signal inten-
sity data were lost for two 10 K arrays (#1013-1 and
#1033-2) after extraction of the allelic calls.
The overall median FGA (both FGA [LOH] and FGA [CN])
was 5%, which was chosen as the cut-off value in the sur-
vival analyses.
Test for differences in chromosome alterations between progressing 
and non-progressing tumors
The average of xij was calculated for tumors in the 2 groups
(progressors and non-progressors) for each SNP, and the
difference dj between the two averages was found. High
and low values of dj were indicative of group differences.
Low values indicated that group 1 had higher mean than
group 2, and high values that group 2 had higher mean.
Long segments of SNPs with high (or low) values of dj
were more likely to be due to true differences; thus the seg-
ment lengths were also calculated. Significance of the
observed statistics was calculated using a permutation
test: New groups of the same sizes were formed by per-
muting group labels 50,000 times and the number of
times (in %) a value higher (or lower) was observed, was
calculated. This test was performed using the combined
dataset (see Additional Files 2 and 3) and using the 50 K
dataset alone, because of the higher resolution of this
dataset (see Additional Files 4 and 5).
Copy number analysis using QPCR
Fifteen unstable chromosomal regions were identified
using the SNP microarray data (see Additional Files 2, 3,
4 and 5). Within these regions, we selected 15 gene loci of
documented or putative bladder cancer relevance (Table
2). To determine relative DNA copy number changes of
these loci, we performed QPCR using an ABI Prism 7500®
Real time PCR cycler (Applied Biosystems, Foster City,
CA) with standard QPCR conditions according to the
manufacturer's instructions (all analyses were performed
in triplicate). Primer sequences are listed in Additional
File 6. Standard curves were constructed using pooled nor-
mal DNA from blood.
We successfully analysed 101 tumors, including 25
tumors analysed on 50 K SNP microarrays. The obtained
quantity values were standardised to mean one by divi-
sion with the median quantity value of the 15 examined
probes (the median value was considered to be most
likely to represent a normal copy number). Results were
log transformed. Normal variation was estimated using
tumors that were stable on 50 K microarrays (FGA < 0.05)
as standard. Quantity values exceeding two times the nor-
mal variation were considered copy number imbalanced.
We used the STATA 8.0 statistical software package (Stata-
Corp LP, College Station, TX).
Results
In total, 67 patients (54%) suffered disease progression,
which was defined as occurrence of muscle invasion
(stage T2-4) or metastatic disease (stage N2-3 or stage
M1). The high progression rate is due to the study design
(exclusion of radically treated patients and patients with
no progression but incomplete follow-up). Fifty-eight
patients showed no evidence of progression. Follow-up
was median 80 months. The median time to progression
was 17 months. Nine patients had longer than five years
progression-free survival, with late progression. We found
CIS concomitant to 38 tumors (31%), with equal distribu-
tion between progressors and non-progressors in this
high-risk material (Table 1).
SNP microarrays (n = 48): Fraction of the genome altered 
(FGA)
The dataset was composed of 22 primary tumors (hereof
21 stage T1), and 26 recurrent tumors (hereof 15 stageBMC Cancer 2009, 9:149 http://www.biomedcentral.com/1471-2407/9/149
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T1). 27 patients had progressing disease, while 21 had no
progression (see Additional File 1 for details). The proba-
bility of later progression was not associated with the frac-
tion of the genome altered (FGA). Figure 1 illustrates the
progression-free survival, dependent on whether the
examined tumor was stable or unstable. Results of all
tumors (corrected for stage) and separately for stage T1
tumors are shown. Figure 2 shows the relative significance
of the FGA and its variation, dependent on whether later
progression occurred or not. The FGA [CN] and FGA
[LOH] for all individual tumors is listed in Additional File
7.
In primary tumors separately (n = 22, hereof 21 stage T1)
we found no difference between tumors with and with no
later progression (p = 0.62 and p = 0.2, for FGA(LOH) and
FGA(CN), respectively; Mann-Whitney ranksum tests).
Recurrent lesions (n = 26, stage T1: n = 15), representing
underlying field disease, even had a slight tendency
towards more stable tumors among those with later pro-
gression (p = 0.08 and p = 0.52; corrected for T-stage).
Equivalent results were obtained using Kaplan-Meier-esti-
mates of progression-free survival time (stable vs. unsta-
ble). Cox' regression analyses, taking into account both
the time to progression and the relative significance of
FGA (in categories), did neither reveal any significant dif-
ferences.
In general, the FGA was significantly higher for stage T1
tumors (p = 0.004 and p = 0.0005) and grade 3 tumors (p
= 0.03 and p = 0.003) compared to stage Ta and grade 2
tumors, respectively. The FGA was also positively corre-
lated to the occurrence of CIS. Notably, eleven tumors
(23%) had very few alterations (FGA < 0.01). Interest-
ingly, seven of these tumors were stage T1, and the disease
progressed in seven of these cases (four stage T1 tumors).
3.2. Test for differences in chromosomal alterations 
related to subsequent progression
This test was performed to reveal specific chromosomal
areas related to subsequent progression. However, the
tumors showed wide chromosomal heterogeneity, which
resulted in a considerable risk of detecting "significance
by chance", supposed the relatively low number of sam-
ples (n = 48) compared to the number of variables (n =
6,400). We employed the fact that all SNPs are mutually
dependent through their mapped positions: a number of
neighbouring "significant" SNPs altered in the same way
were more likely to represent true changes (segment anal-
ysis). Genome-wide differences are shown in Additional
Files 2 and 3 (Combined dataset, CN and LOH differ-
ences, respectively), and with the higher resolution of the
50 K dataset in Additional Files 4 and 5.
Using a combined approach of LOH and copy number
analysis with restriction to changes more pronounced in
progressing tumors (and thus independent of stage), we
identified some areas which may play a role in the pro-
gression of bladder cancer (Table 3). Most prominent was
loss/LOH of chromosome 8p11-p12 (35–43 Mb). To
reveal statistic significance of these segments, we per-
formed a permutation analysis. However, none of the
Table 2: Selected gene loci, gene IDs, cytoband and genomic annotation of the amplicons used for QPCR validation.
Gene Gene-ID Cytoband Amplicon position (NCBI Build 35.1 [hg17]) Amplicon position (hg18)
S100A8 6279 1q21 chr1:150,175,956–150,176,071 chr1:151,629,507–151,629,622
FN1 2335 2q34 chr2:216,112,380–216,112,466 chr2:215,995,119–215,995,205
RAF1 5894 3p25 chr3:12,635,039–12,635,148 Identical
DAB2 1601 5p13 chr5:39,418,493–39,418,602 identical
CSPG2 1462 5q14.3 chr5:82,821,732–82,821,832 identical
E2F3 1871 6p22 chr6:20,598,410–20,598,516 identical
SFRP1 6422 8p12-p11.1 chr8:41,285,606–41,285,686 identical
TUSC3 7991 8p22 chr8:15,524,970–15,525,081 identical
EDD1 51366 8q22 chr8:103,366,989–103,367,080 identical
MYC 4609 8q24.12-q24.13 chr8:128,822,158–128,822,287 identical
CDKN2A 1029 9p21 chr9:21,957,845–21,957,973 identical
KLF4 9314 9q31 chr9:107,331,117–107,331,240 chr9:109,291,383–109,291,506
MDM2 4193 12q14.3-q15 chr12:67,519,751–67,519,858 Identical
RB1 5925 13q14.2 chr13:47,853,426–47,853,564 Identical
TP53 7157 17p13.1 chr17:7,520,091–7,520,236 Identical
Loci were selected based on the frequency of alterations in the total SNP material, and on bladder cancer relevance according to literature and our 
own gene expression analyses [22]. Loci are not referring to the (insignificant) relative changes characterizing progressing tumors listed on Table 3, 
except SFRP1 (8p11). Primer sets leading to amplicons of 80–120 basepairs were designed using the Primer3 software http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3.cgi. The QPCR primer sequences are listed in Additional File 6.BMC Cancer 2009, 9:149 http://www.biomedcentral.com/1471-2407/9/149
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identified areas was significant in segment analysis
(Table 3).
3.3. Copy number analysis of 15 selected gene loci using 
QPCR (101 tumors, Figure 3)
A semi quantitative illustration of the results in all tumors
is given on Figure 3. We confirmed that stage T1 tumors
had significantly more alterations than stage Ta tumors (p
= 0.008, Mann-Whitney-test). In congruence with the
microarray results, there was no correlation between the
number of alterations and subsequent progression. QPCR
data showed good association with the data obtained
from 50 K microarrays (r = 0.67). However, no correlation
between any of the markers and the risk of progression
was found, including the SFRP1 marker (8p11-p12). Nei-
ther did we find significant influence of any confounder
studied, including age, gender, multiplicity, primary/sec-
ondary, concomitant CIS, and BCG-treatment, in multi-
variate analyses. The number of changed markers for all
individual tumors is listed in Additional File 7.
Discussion
The aim of the present study was to investigate inherent
chromosomal changes related to the risk of progression in
bladder cancer, as well as chromosomal instability (CI)/
fraction of the genome altered (FGA) as a prognostic
marker. A previous CGH study of 54 stage T1 tumors sug-
gested a shorter progression free survival of tumors with
multiple copy number losses (CI) or alterations at certain
regions [8]. We utilised SNP microarrays to perform high-
resolution genome-wide combined LOH and copy
number screening of 21 primary stage T1 tumors. We
Kaplan Meier estimates of progression-free survival according to chromosomal instability (CI) Figure 1
Kaplan Meier estimates of progression-free survival according to chromosomal instability (CI). Tumors are 
divided in stable and unstable using a cut-off for the fraction of the genome altered (FGA) > 0.05. Here, the influence of the 
time to progression, not the relative size of the FGA is analysed. Logrank-tests for differences between progressing and non-
progressing tumors showed no significant difference. A: all tumors, CI based on copy number changes (n = 46). B: all tumors, 
CI based on LOH (n = 47). C: Stage T1 tumors only, CI based on copy number changes (n = 32). D: Stage T1 tumors only, CI 
based on LOH (n = 33).
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demonstrated frequent chromosomal changes in most of
these tumors. However, we were not able to show any
association between chromosomal changes and subse-
quent progression. One explanation may be that stage T1
tumors can be completely resected. Under this condition,
the future course is not determined by the malignant
potential of the resected tumor, but the residual tumor
cells in the bladder.
Recurrent tumors are usually the result of the spread of a
single tumor clone in the urothelium. Only a minority has
been shown to be of different clonal origin, i.e. new pri-
mary tumors [18]. We analysed 26 recurrent tumors, to
determine whether residual tumor cells in the bladder
already harbour changes related to the risk of progression,
because these changes should be present in all recurrences
as well. Our results demonstrated less frequent chromo-
somal alterations in non-invasive recurrences (stage Ta),
even if the primary lesion was stage T1, and the disease
later progressed. Recurrent stage T1 tumors had as much
alterations as the primary stage T1 tumors; however, this
was again independent of later progression. These results
indicated that the precursor lesions of recurrent tumors –
also those with later progression – had relatively few alter-
ations, i.e. they were apparently chromosomal stable. The
frequent alterations seen in stage T1 (and muscle-inva-
sive) tumors were then the results of (more or less) sto-
chastic events during the development of the individual
tumor, and not inherent characteristics of field changes
with high malignant potential. These findings are well in-
line with the "field-first-tumor-later" concept recently
developed by Höglund [19], according to which recurring
The fraction of the genome altered (FGA) against the clinical course (progression/no progression), separately for copy number  changes (left) and LOH (right) Figure 2
The fraction of the genome altered (FGA) against the clinical course (progression/no progression), separately 
for copy number changes (left) and LOH (right). Non-progressing tumors in triangles, progressing in diamonds. Solid 
symbols indicate stage T1 tumors. Ranksum-tests for difference in FGA between progressing and non-progressing tumors for 
all tumors (n = 48) and for stage T1 tumors only (n = 33) showed no significant difference. Here, the relative size of the FGA, 
not the influence of the time to progression is analysed.
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tumors originate from a shared field of premalignant cells
(with relatively few chromosomal changes) and not from
previous overt tumors. Consequently, it was impossible to
predict the future course of a disease from chromosomal
changes of a marker lesion, given that this lesion was com-
pletely resected. Notably, about 25% of the tumors
showed virtually no CI. This was independent of stage,
concomitant CIS, and future progression. In conclusion,
with the huge variation of chromosomal changes demon-
strated, chromosomal alterations are unlikely to play a
role as a predictive instrument in non-muscle invasive
bladder cancer – at least with the resolution provided
here, which is higher than in the previous report [8].
The same considerations also apply with respect to spe-
cific chromosomal alterations. The paper of Richter et al.
[8] suggested several specific chromosomal changes that
may have significance for the malignant development
independent of general CI. Unfortunately, we were not
able to confirm these results. The identification of signifi-
cant areas among many possible areas is challenging,
given the variation of chromosomal changes observed. If
the number of possible areas (here: SNPs) by far exceeds
the number of samples, conventional statistical methods
do not perform well. Correction for multiple comparisons
is mandatory. In our segment analysis, we employed the
dependency of the SNPs on their mapped positions to
reduce the number of variables from 6,400 (SNPs) to 22
(chromosomes). This permutation analysis reveals the
probability of finding a segment of significant SNPs of a
given length on a given chromosome by chance. However,
this analysis must fail to identify small significant seg-
ments, particularly on chromosomes with common large-
scale alterations, e.g. chromosome 8.
We had the intention to validate the predictive potential
of specific chromosomal areas using QPCR-based copy-
number analysis. Since no significant areas could be doc-
umented (Table 3), we decided to evaluate general CI
using areas with frequent instability (see Additional Files
2, 3, 4 and 5) and possible bladder cancer relevance,
according to the literature (including [8]) and our own
gene expression analyses. We did not find any correlation
between the risk of progression and any of the chosen
markers, or with the number of changed markers/CI.
These results were in line with the SNP-data. However, the
area on chromosome 8p11 deserves special attention. Not
only did we pinpoint the area as significant in SNP analy-
ses (Table 3), it has also previously been stressed as being
very unstable not only in bladder cancer, but in many
other solid cancers [20]. The area has been reported to be
frequently involved in chromosomal rearrangements
[20]. Candidate genes in this region include SFRP1. Chro-
mosomal loss and reduced expression of the mRNA and
the SFRP1 protein, an antagonist of Wnt-signalling, have
been reported by several other groups to be associated
with bladder cancer progression [21], and we found the
same in our own gene expression profiles [22]. In QPCR
analysis, the SFRP1 marker was very unstable; however,
this was not related to progression free survival. The clin-
ical significance of this region still remains to be eluci-
dated.
We adjusted for the grade of dysplasia, an important risk
factor for the clinical risk estimation, using the Bergkvist
grading system under routine conditions [15]. This system
has been in routine use all over Scandinavia for many
years, but is uncommon in the rest of the world. It can be
translated into the 1999 WHO/ISUP grading system [23],
according to which most of our tumors would be classi-
fied as "high grade". A pathological review of the slides
would have been optimal, but was not performed. How-
ever, we considered the grading system of minor impor-
tance, as long as the analysis is adjusted for this factor.
Table 3: Candidate areas with chromosomal alterations characterizing non-muscle invasive bladder cancers with subsequent 
progression.
Chromosome Cytoband Physical position 
(hg17/NCBI build 35.1)
chromosomal changes of 
progressing tumors
Candidate genes 
(selection)
p (single SNPs) p (segment)
1 p31.1-p22.3 82–86 Mb CN gain BCL10 0.003 n.s.
2 q33.3-q34 208–213 Mb CN gain CREB1, MAP2 0.001 0.05
3 p21-p14.3 42–64 Mb CN gain CCR-cluster 0.01 n.s.
4 p13 40–45 Mb CN loss/LOH 0.02 n.s.
6 q15-q23.2 89–133 Mb CN loss/LOH TPD52L1 0.01 n.s.
8 p12-p11.21 33 M–43 Mb CN loss/LOH SFRP1, TACC1, FGFR1 0.01 n.s.
10 p15.1-p14 3.5 M–13 Mb CN gain GATA3, NET1, PKCQ, 
IL15RA
0.005 n.s.
10 p11 30–36 Mb CN gain 0.005 n.s.
15 q25.3 84–85 Mb CN loss 0.01 n.s.
SNP microarray analysis (significance p = probability of detecting difference between progressing and non-progressing tumors by chance, 
permutation analysis). A survey of the entire genome is possible in Additional Files 2, 3, 4 and 5.BMC Cancer 2009, 9:149 http://www.biomedcentral.com/1471-2407/9/149
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Conclusion
Chromosomal instability did not characterise tumors
with subsequent progression. Our results suggest that
chromosomal instability develops during the progression
process, and is rare in precursor lesions, as indicated by
the less pronounced chromosomal changes in recurrent
tumors. Chromosomal alterations, particularly losses, of
chromsome 8p11 (34–43 Mb) may be present in field dis-
ease, and may have a role in its malignant development.
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Copy number analysis of 15 marker regions (see Table 2) Figure 3
Copy number analysis of 15 marker regions (see Table 2). A: Kaplan Meier estimates of progression free survival 
according to number of copy-number imbalanced marker regions in QPCR analysis. Stable (0–2 changes); intermediate (3–4 
changes), unstable (> 4 changes). B: Copy number alterations (log2 ratios) of candidate regions determined by SNP microar-
rays (SNPs flanking the marker regions). Tumors in columns, marker regions in rows. Top row indicates patient and tumor ID, 
bars below refer to tumor characteristics. Non-progressors to the left, progressors to the right; stage T1 tumors in the mid-
dle, stage Ta tumors on the flanks. Tumors are further sorted according to their CIS status: Tumors with concomitant CIS in 
the very center and on the very verges, tumors with later or no CIS in between. Furthermore, the grade of dysplasia (Berg-
kvist[15]), the actual clinical risk (including previous history)[3] and the used microarray (1 = 50 K, 2 = 10 K) are indicated. 
Data area: Red: Copy number gain. Blue: Copy number loss. C: Copy number analysis of the same candidate regions by QPCR 
of 101 tumors, hereof 77 independent tumors. Tumors are sorted in the same way as in B. A survey of the number of altered 
regions is provided in Additional File 7.
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